Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03945292 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
A Phase 2 study, sponsored by Arrowhead Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT03945292 is a Phase 2 study that has completed, run by Arrowhead Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT03945292, a Phase 2 study, has completed, sponsored by Arrowhead Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
Interventions
- OTHER Placebo
- DRUG Fazisiran Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2023-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03945292
The ClinicalTrials.gov registry entry for NCT03945292 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arrowhead Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03945292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03945292 about?
NCT03945292 is a clinical study titled "Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)". The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
What is the current status of trial NCT03945292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-08-07. Estimated completion is 2023-09-18.
What interventions are being tested in trial NCT03945292?
The interventions under investigation include: Placebo (OTHER), Fazisiran Injection (DRUG).
Who is sponsoring clinical trial NCT03945292?
This trial is sponsored by Arrowhead Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.